İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2024 · article

Humoral Response Decreases in Hemodialysis Patients 6 Months After The Third Dose of COVID-19 Vaccine

Dergi Journal of European Internal Medicine Professionals
ISSN2980-0617
YÖKSİS OpenAlex Açık erişim · green
Yıl2024
Atıf0OpenAlex
Yüzdelik%44,4
FWCI0,01,00 = dünya ortalaması

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıJournal of European Internal Medicine Professionals
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

OpenAlex İngilizce

Background: This study evaluated the antibody levels six months after the administration of the third dose of the COVID-19 vaccine in hemodialysis patients. Methods: A total of 52 hemodialysis patients were enrolled in the study. Antibody levels were assessed using the Abbott SARS-CoV-2 immunoassay, designed to detect IgG antibodies targeting the receptor-binding domain of the S1 subunit of the SARS-CoV-2 spike protein. Results: The incidence of COVID-19 infection within six months following the third vaccine dose was 29.6% (8 patients: 2 males, 25%; 6 females, 75%). Among patients who did not contract COVID-19 within this period, 9 were male (47.4%) and 10 were female (52.6%). There was no statistically significant association between gender and the incidence of COVID-19 within six months post-vaccination (p= 0.280). The median antibody level post-third dose was 7332.4 AU/mL (range: 10.5–40,000), which significantly decreased at the sixth month to 3238.4 AU/mL (range: 17–29,994.7) (p= 0.001). No significant difference between male and female patients was observed in the sixth-month antibody titers (p= 0.744). Furthermore, when analyzed by vaccine type, there was no statistically significant difference in the decline of SARS-CoV-2 IgG antibody levels between recipients of CoronaVac/Sinovac and BNT162b2 (Pfizer/BioNTech) [median (min-max) antibody levels: CoronaVac/Sinovac 2398.2 AU/mL (59.2–38,981.5); BNT162b2 (Pfizer/BioNTech) 11,325.7 AU/mL (17–40,000), (p= 0.181)] at the end of the sixth month. Conclusion: Antibody titers in hemodialysis patients significantly decreased by the end of the sixth month following the third dose of the SARS-CoV-2 vaccine, independent of the vaccine type. This decline highlights the potential necessity for additional booster doses to enhance and maintain immune protection against SARS-CoV-2 in this vulnerable population.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

0atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yazarlar

8
  1. DEMET YAVUZ 1
  2. AYŞE KEVSER DEMİR 2
  3. MUHAMMED ALİ ORUÇ 3
  4. ZAFER ERCAN 4
  5. ÖZNUR KUL 5
  6. EŞE AKBULUT 6
  7. ERDİNÇ YAVUZ 7
  8. MEHMET DERYA DEMİRAĞ SAMSUN ÜNİVERSİTESİ 8